BACKGROUND: Rhinovirus (RV) is the main cause of asthma exacerbations in children. Some studies reported that persons with asthma have attenuated interferon (IFN) responses to experimental RV infection compared with healthy individuals. However, responses to community-acquired RV infections in controls and children with asthma have not been compared. OBJECTIVE: To evaluate nasal cytokine responses after natural RV infections in people with asthma and healthy children. METHODS: We compared nasal cytokine expression among controls and children with asthma during healthy, virus-negative surveillance weeks and self-reported RV-positive sick weeks. A total of 14 controls and 21 patients with asthma were studied. Asthma disease severity was based on symptoms and medication use. Viral genome was detected by multiplex polymerase chain reaction. Nasal cytokine protein levels were determined by multiplex assays. RESULTS: Two out of 47 surveillance weeks tested positive for RV, illustrating an asymptomatic infection rate of 5%. A total of 38 of 47 sick weeks (81%) tested positive for the respiratory virus. Of these, 33 (87%) were positive for RV. During well weeks, nasal interleukin 8 (IL-8), IL-12, and IL-1β levels were higher in children with asthma than controls. Compared with healthy virus-negative surveillance weeks, IL-8, IL-13, and interferon beta increased during colds only in patients with asthma. In both controls and children with asthma, the nasal levels of interferon gamma, interferon lambda-1, IL-1β, IL-8, and IL-10 increased during RV-positive sick weeks. During RV infection, IL-8, IL-1β, and tumor necrosis factor-α levels were strongly correlated. CONCLUSION: In both controls and patients with asthma, natural RV infection results in robust type II and III IFN responses.
BACKGROUND: Rhinovirus (RV) is the main cause of asthma exacerbations in children. Some studies reported that persons with asthma have attenuated interferon (IFN) responses to experimental RV infection compared with healthy individuals. However, responses to community-acquired RV infections in controls and children with asthma have not been compared. OBJECTIVE: To evaluate nasal cytokine responses after natural RV infections in people with asthma and healthy children. METHODS: We compared nasal cytokine expression among controls and children with asthma during healthy, virus-negative surveillance weeks and self-reported RV-positive sick weeks. A total of 14 controls and 21 patients with asthma were studied. Asthma disease severity was based on symptoms and medication use. Viral genome was detected by multiplex polymerase chain reaction. Nasal cytokine protein levels were determined by multiplex assays. RESULTS: Two out of 47 surveillance weeks tested positive for RV, illustrating an asymptomatic infection rate of 5%. A total of 38 of 47 sick weeks (81%) tested positive for the respiratory virus. Of these, 33 (87%) were positive for RV. During well weeks, nasal interleukin 8 (IL-8), IL-12, and IL-1β levels were higher in children with asthma than controls. Compared with healthy virus-negative surveillance weeks, IL-8, IL-13, and interferon beta increased during colds only in patients with asthma. In both controls and children with asthma, the nasal levels of interferon gamma, interferon lambda-1, IL-1β, IL-8, and IL-10 increased during RV-positive sick weeks. During RV infection, IL-8, IL-1β, and tumor necrosis factor-α levels were strongly correlated. CONCLUSION: In both controls and patients with asthma, natural RV infection results in robust type II and III IFN responses.
Authors: Weimin Liu; Sucai Liu; Mukesh Verma; Iram Zafar; James T Good; Donald Rollins; Stephen Groshong; Magdalena M Gorska; Richard J Martin; Rafeul Alam Journal: J Allergy Clin Immunol Date: 2016-10-01 Impact factor: 10.793
Authors: Annette T Hastie; Wendy C Moore; Deborah A Meyers; Penny L Vestal; Huashi Li; Stephen P Peters; Eugene R Bleecker Journal: J Allergy Clin Immunol Date: 2010-04-15 Impact factor: 10.793
Authors: Michelle A Gill; Andrew H Liu; Agustin Calatroni; Rebecca Z Krouse; Baomei Shao; Allison Schiltz; James E Gern; Alkis Togias; William W Busse Journal: J Allergy Clin Immunol Date: 2017-09-01 Impact factor: 10.793
Authors: E Kathryn Miller; Johanna Zea Hernandez; Vera Wimmenauer; Bryan E Shepherd; Diego Hijano; Romina Libster; M Elina Serra; Niranjan Bhat; Juan P Batalle; Yassir Mohamed; Andrea Reynaldi; Andrea Rodriguez; Monica Otello; Nestor Pisapia; Jimena Bugna; Miguel Bellabarba; David Kraft; Silvina Coviello; F Martin Ferolla; Aaron Chen; Stephanie J London; George K Siberry; John V Williams; Fernando P Polack Journal: Am J Respir Crit Care Med Date: 2011-12-01 Impact factor: 21.405
Authors: Meghan H Shilts; Christian Rosas-Salazar; Andrey Tovchigrechko; Emma K Larkin; Manolito Torralba; Asmik Akopov; Rebecca Halpin; R Stokes Peebles; Martin L Moore; Larry J Anderson; Karen E Nelson; Tina V Hartert; Suman R Das Journal: Microb Ecol Date: 2015-09-14 Impact factor: 4.552
Authors: S Kling; H Donninger; Z Williams; J Vermeulen; E Weinberg; K Latiff; R Ghildyal; P Bardin Journal: Clin Exp Allergy Date: 2005-05 Impact factor: 5.018
Authors: Joshua L Kennedy; Marcus Shaker; Victoria McMeen; James Gern; Holliday Carper; Deborah Murphy; Wai-Ming Lee; Yury A Bochkov; Rose F Vrtis; Thomas Platts-Mills; James Patrie; Larry Borish; John W Steinke; William A Woods; Peter W Heymann Journal: Am J Respir Crit Care Med Date: 2014-03-01 Impact factor: 21.405
Authors: Peter A B Wark; Sebastian L Johnston; Fabio Bucchieri; Robert Powell; Sarah Puddicombe; Vasile Laza-Stanca; Stephen T Holgate; Donna E Davies Journal: J Exp Med Date: 2005-03-21 Impact factor: 14.307
Authors: T C Lewis; T A Henderson; A R Carpenter; I A Ramirez; C L McHenry; A M Goldsmith; X Ren; G B Mentz; B Mukherjee; T G Robins; T A Joiner; L S Mohammad; E R Nguyen; M A Burns; D T Burke; M B Hershenson Journal: Clin Exp Allergy Date: 2012-12 Impact factor: 5.018